GURUFOCUS.COM » STOCK LIST » USA » NYSE » Boston Scientific Corp (NYSE:BSX) » Definitions » Financial Strength
Switch to:

Boston Scientific Financial Strength

: 5 (As of Jun. 2022)
View and export this data going back to 1992. Start your Free Trial

Boston Scientific has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Boston Scientific's Interest Coverage for the quarter that ended in Jun. 2022 was 8.09. Boston Scientific's debt to revenue ratio for the quarter that ended in Jun. 2022 was 0.72. As of today, Boston Scientific's Altman Z-Score is 2.97.


Competitive Comparison

For the Medical Devices subindustry, Boston Scientific's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Boston Scientific Financial Strength Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Financial Strength distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Financial Strength falls into.



Boston Scientific Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Boston Scientific's Interest Expense for the months ended in Jun. 2022 was $-64 Mil. Its Operating Income for the months ended in Jun. 2022 was $518 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $9,157 Mil.

Boston Scientific's Interest Coverage for the quarter that ended in Jun. 2022 is

Interest Coverage=-1*Operating Income (Q: Jun. 2022 )/Interest Expense (Q: Jun. 2022 )
=-1*518/-64
=8.09

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Boston Scientific's Debt to Revenue Ratio for the quarter that ended in Jun. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(170 + 9157) / 12976
=0.72

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Boston Scientific has a Z-score of 2.97, indicating it is in Grey Zones. This implies that Boston Scientific is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.97 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boston Scientific  (NYSE:BSX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Boston Scientific has the Financial Strength Rank of 5.


Boston Scientific Financial Strength Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific Business Description

Boston Scientific logo
Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Executives
Wichmann David S director UNITEDHEALTH GROUP INC 9900 BREN RD E MINNETONKA MN 55343
Brown Vance R officer: SVP, GC and Corp. Secretary C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Olson Scott officer: SVP & Pres, Rhythm Management C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Scanlon Meghan officer: SVP,Pres,Urology Pelvic Health C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Monson Jonathan officer: VP, Corp Controller and CAO C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Fujimori Yoshiaki director 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
James Donna director ONE MIRANOVA PLACE SUITE 1040 COLUMBUS OH 43215
Zane Ellen M director C/O TUFTS-NEW ENGLAND MEDICAL CENTER 750 WASHINGTON STREET, TUFTS-NEMC #451 BOSTON MA 02111
Sununu John E director C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Connors Nelda J director BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234
Ludwig Edward J director C/O BECTON DICKERSON & CO 1 BECTON DR FRANKLIN LAKES NJ 07417
Roux David J director C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752
Dockendorff Charles J director COVIDIEN LTD. 15 HAMPSHIRE STREET MANSFIELD MA 02048
Macmillan Stephen P director 250 CAMPUS DRIVE MARLBOROUGH MA 01752
Wang Xin Warren officer: SVP and Pres, Asia Pacific C/O BOSTON SCIENTIFIC CORPORATION 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752

Boston Scientific Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)